The UK medicines regulator has authorized Eli Lilly’s once-daily weight-loss pill Foundayo for weight management and type 2 diabetes, making Britain the first European country to clear the oral GLP-1 treatment. The drug is not yet available on the NHS pending a health technology appraisal.
Eli Lilly has secured a major regulatory milestone in Europe as British health authorities cleared its oral GLP-1 treatment for weight management and type 2 diabetes. The Medicines and Healthcare products Regulatory Agency authorised the once-daily pill, known generically as orforglipron and marketed as Foundayo, making the UK the first country on the continent to greenlight the medication.
The announcement immediately lifted market sentiment, pushing shares of the Indianapolis-based pharmaceutical manufacturer up by over 2% during morning trading. Yet, despite the regulatory clearance, patients will face an immediate waiting period before prescriptions can be filled.
Regulatory Clearance and Clinical Efficacy
Orforglipron operates differently from foundational injectable treatments by utilizing a small-molecule, non-peptide structure. This chemical composition allows patients to take the tablet at any time of day without navigating food or water restrictions.
Clinical trials supporting the application demonstrated substantial physical reductions. In the ATTAIN-1 study involving 3,127 adults with obesity, participants receiving a 36 mg dose achieved a mean weight loss of 11.2% over 72 weeks, compared with a 2.1% reduction for those given a placebo. Within that same strength cohort, more than half of participants lost at least 10% of their body weight.
Efficacy also extended to metabolic control. Data from the ACHIEVE-1 evaluation showed that among 559 individuals with early type 2 diabetes, HbA1c levels fell by 1.47 percentage points at the 12 mg strength and 1.48 points at the 36 mg strength after 40 weeks, versus a 0.41-point drop in the placebo group.
NHS Access Status and the Road to Reimbursement
While the regulatory green light establishes commercial authorization, access remains restricted in the near term. The MHRA explicitly noted that Whilst this tablet is approved for use in the UK, it is not available currently via the NHS.
“Following rigorous assessment of orforglipron’s safety, quality, and effectiveness, we are pleased to be the first regulator in Europe to authorise this tablet for weight management and type 2 diabetes.”
Julian Beach, MHRA executive director of healthcare quality and access
The treatment must now clear the National Institute for Health and Care Excellence, whose health technology appraisal and reimbursement decision is due on 18 November 2026. That evaluation will determine whether the drug secures funding within the health service. Until then, officials emphasize that it remains a prescription-only medication obtainable exclusively through registered channels, warning patients against unverified online sellers.
Competition in the Oral Obesity Treatment Market
The British rollout inserts Eli Lilly into a direct commercial showdown with Novo Nordisk, whose competing oral Wegovy pill secured prior approval in the UK. Globally, the race for market share in oral weight-loss therapies has intensified rapidly.
In the United States, Lilly’s GLP-1 tablet has gained momentum since its launch in April. Market data from the broader prescription space indicates that Foundayo has captured roughly 11% of new prescription volumes for obesity pills since its rollout, with Novo Nordisk’s competing oral treatment maintaining the remainder of that specific segment.
With regulatory hurdles cleared in Britain, pricing strategy, manufacturing scale, and the upcoming NICE appraisal will dictate how quickly the medication transitions from hospital authorizations to everyday clinical practice.